Related references
Note: Only part of the references are listed.Survival after Resection of Pancreatic Adenocarcinoma: Results from a Single Institution over Three Decades
Jordan M. Winter et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker
L. Khoja et al.
BRITISH JOURNAL OF CANCER (2012)
Cancer Statistics, 2012
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2012)
Identification of Serum Biomarker Signatures Associated with Pancreatic Cancer
Christer Wingren et al.
CANCER RESEARCH (2012)
EMT and Dissemination Precede Pancreatic Tumor Formation
Andrew D. Rhim et al.
CELL (2012)
The Pancreas Cancer Microenvironment
Christine Feig et al.
CLINICAL CANCER RESEARCH (2012)
Serum MicroRNA Expression Profile as a Biomarker in the Diagnosis and Prognosis of Pancreatic Cancer
Rui Liu et al.
CLINICAL CHEMISTRY (2012)
Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma
Raphael Marechal et al.
GASTROENTEROLOGY (2012)
Urine Metabolic Signature of Pancreatic Ductal Adenocarcinoma by 1H Nuclear Magnetic Resonance: Identification, Mapping, and Evolution
Claudia Napoli et al.
JOURNAL OF PROTEOME RESEARCH (2012)
Feasibility of Fecal MicroRNAs as Novel Biomarkers for Pancreatic Cancer
Alexander Link et al.
PLOS ONE (2012)
A Novel Survival-Based Tissue Microarray of Pancreatic Cancer Validates MUC1 and Mesothelin as Biomarkers
Jordan M. Winter et al.
PLOS ONE (2012)
Circulating Tumor Cells in Melanoma Patients
Gary A. Clawson et al.
PLOS ONE (2012)
Invasive Carcinoma Arising in Intraductal Papillary Mucinous Neoplasms of the Pancreas A Matched Control Study with Conventional Pancreatic Ductal Adenocarcinoma
Adam C. Yopp et al.
ANNALS OF SURGERY (2011)
Pancreatic Cancer Surgery in the New Millennium Better Prediction of Outcome
Werner Hartwig et al.
ANNALS OF SURGERY (2011)
Metabolomic Profiling of Serum from Human Pancreatic Cancer Patients Using 1H NMR Spectroscopy and Principal Component Analysis
Dong OuYang et al.
APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY (2011)
Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer
R. Morimura et al.
BRITISH JOURNAL OF CANCER (2011)
Feasibility of Identifying Pancreatic Cancer Based on Serum Metabolomics
Oliver F. Bathe et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2011)
Circulating Tumor Cells as Biomarkers in Prostate Cancer
Daniel C. Danila et al.
CLINICAL CANCER RESEARCH (2011)
Serum Biomarker Panels for the Detection of Pancreatic Cancer
Randall E. Brand et al.
CLINICAL CANCER RESEARCH (2011)
Detection of Differentially Expressed microRNAs in Serum of Pancreatic Ductal Adenocarcinoma Patients: miR-196a Could Be a Potential Marker for Poor Prognosis
Xiangyu Kong et al.
DIGESTIVE DISEASES AND SCIENCES (2011)
The Clinical Utility and Limitations of Serum Carbohydrate Antigen (CA19-9) as a Diagnostic Tool for Pancreatic Cancer and Cholangiocarcinoma
Sundeep Singh et al.
DIGESTIVE DISEASES AND SCIENCES (2011)
Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by Chemoradiation With Cetuximab for Locally Advanced (T4) Pancreatic Adenocarcinoma: Correlation of Smad4(Dpc4) Immunostaining With Pattern of Disease Progression
Christopher H. Crane et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known BRCA Mutation: Clinical Descriptors, Treatment Implications, and Future Directions
Maeve A. Lowery et al.
ONCOLOGIST (2011)
Tissue and Serum microRNAs in the KrasG12D Transgenic Animal Model and in Patients with Pancreatic Cancer
Joseph J. LaConti et al.
PLOS ONE (2011)
Prognostic Impact of Perioperative Serum CA 19-9 Levels in Patients with Resectable Pancreatic Cancer
Naru Kondo et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy
Nazik Hammad et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2010)
Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis
A. Xue et al.
BRITISH JOURNAL OF CANCER (2010)
Gemcitabine Metabolic and Transporter Gene Polymorphisms Are Associated With Drug Toxicity and Efficacy in Patients With Locally Advanced Pancreatic Cancer
Motofumi Tanaka et al.
CANCER (2010)
Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers
Daniel D. Von Hoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A Six-Gene Signature Predicts Survival of Patients with Localized Pancreatic Ductal Adenocarcinoma
Jeran K. Stratford et al.
PLOS MEDICINE (2010)
CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions
Daniele Marrelli et al.
AMERICAN JOURNAL OF SURGERY (2009)
Carbohydrate Antigen 19-9 Change During Chemotherapy for Advanced Pancreatic Adenocarcinoma
Michele Reni et al.
CANCER (2009)
MicroRNAs in Plasma of Pancreatic Ductal Adenocarcinoma Patients as Novel Blood-Based Biomarkers of Disease
Jin Wang et al.
CANCER PREVENTION RESEARCH (2009)
The Role of HuR in Gemcitabine Efficacy in Pancreatic Cancer: HuR Up-regulates the Expression of the Gemcitabine Metabolizing Enzyme Deoxycytidine Kinase
Christina L. Costantino et al.
CANCER RESEARCH (2009)
Identification of serum biomarkers for pancreatic adenocarcinoma by proteomic analysis
Jinghui Guo et al.
CANCER SCIENCE (2009)
The identification of phosphoglycerate kinase-1 and histone H4 autoantibodies in pancreatic cancer patient serum using a natural protein microarray
Tasneem H. Patwa et al.
ELECTROPHORESIS (2009)
The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status
Rodrigo Jover et al.
EUROPEAN JOURNAL OF CANCER (2009)
Association of GUCY2C Expression in Lymph Nodes With Time to Recurrence and Disease-Free Survival in pN0 Colorectal Cancer
Scott A. Waldman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer
Christine A. Iacobuzio-Donahue et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
CA 19-9 Velocity Predicts Disease-Free Survival and Overall Survival After Pancreatectomy of Curative Intent
Jonathan M. Hernandez et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2009)
Predictive and Prognostic Value of CA 19-9 in Resected Pancreatic Adenocarcinoma
Joshua G. Barton et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2009)
New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer
Rahul Pannala et al.
LANCET ONCOLOGY (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma
H. Akita et al.
ONCOGENE (2009)
Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene
Sian Jones et al.
SCIENCE (2009)
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Matthew G. Vander Heiden et al.
SCIENCE (2009)
A Compendium of Potential Biomarkers of Pancreatic Cancer
H. C. Harsha et al.
PLOS MEDICINE (2009)
The Impact of Resection Margin Status and Postoperative CA19-9 Levels on Survival and Patterns of Recurrence After Postoperative High-Dose Radiotherapy With 5-FU-Based Concurrent Chemotherapy for Resectable Pancreatic Cancer
Timothy J. Kinsella et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2008)
Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer
Sandra Perez-Torras et al.
BIOCHEMICAL PHARMACOLOGY (2008)
Stromal SPARC expression and patient survival after chemoradiation for non-resectable pancreatic adenocarcinoma
Tine S. Mantoni et al.
CANCER BIOLOGY & THERAPY (2008)
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma - A randomized controlled trial
William F. Regine et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy
John C. Cheville et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Postresection CA 19-9 Predicts Overall Survival in Patients With Pancreatic Cancer Treated With Adjuvant Chemoradiation: A Prospective Validation by RTOG 9704
Adam C. Berger et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study
Dominik R. Berthold et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study
Kerby Shedden et al.
NATURE MEDICINE (2008)
Serum CA19-9 Decline Compared to Radiographic Response as a Surrogate for Clinical Outcomes in Patients With Metastatic Pancreatic Cancer Receiving Chemotherapy
Derrick Wong et al.
PANCREAS (2008)
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
Sian Jones et al.
SCIENCE (2008)
Isolation of rare circulating tumour cells in cancer patients by microchip technology
Sunitha Nagrath et al.
NATURE (2007)
Human papillomavirus DNA versus papanicolaou screening tests for cervical cancer
Marie-Helene Mayrand et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma
Jeffrey R. Infante et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer - A Randomized controlled trial
Helmut Oettle et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Targeting Fanconi anemia/BRCA2 pathway defects in cancer: The significance of preclinical pharmacogenornic models
Eike Gallmeier et al.
CLINICAL CANCER RESEARCH (2007)
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer
Gershon Y. Locker et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma
Cristina R. Ferrone et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Overexpression and elevated serum levels of phosphoglycerate kinase 1 in pancreatic ductal adenocarcinoma
TL Hwang et al.
PROTEOMICS (2006)
Diagnostic performance of digital versus film mammography for breast-cancer screening
ED Pisano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials
NR Maisey et al.
BRITISH JOURNAL OF CANCER (2005)
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer
E Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population
JE Kim et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2004)
Comprehensive proteomic analysis of human pancreatic juice
M Gronborg et al.
JOURNAL OF PROTEOME RESEARCH (2004)
Circulating tumor cells, disease progression, and survival in metastatic breast cancer
M Cristofanilli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Analysis of gene expression in cancer cell lines identifies candidate markers for pancreatic tumorigenesis and metastasis
E Missiaglia et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine
C Ziske et al.
BRITISH JOURNAL OF CANCER (2003)
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer
CM Ribic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays
CA Iacobuzio-Donahue et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
Mitoxantrone in progressive multiple sclerosis:: a placebo-controlled, double-blind, randomised, multicentre trial
HP Hartung et al.
LANCET (2002)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
GD Demetri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Intraoperative molecular detection of circulating tumor cells by reverse transcription-polymerase chain reaction in patients with biliary-pancreatic cancer is associated with hematogenous metastasis
K Uchikura et al.
ANNALS OF SURGICAL ONCOLOGY (2002)
Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone:: Results of study Acute Myeloid Leukemia -: Berlin-Frankfurt-Munster 93
U Creutzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Cisplatin, cytarabine, caffeine, and continuously infused 5-fluorouracil (PACE) in the treatment of advanced pancreatic carcinoma - A phase II study
S Ahmed et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2000)
Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection
K Yamaguchi et al.
ANNALS OF SURGERY (2000)